Information aids influence more to get screened for colon cancer

November 6, 2012 by Glenda Fauntleroy, Health Behavior News Service

People who are given information tools to help them decide whether to have a colorectal cancer screening test are more likely to request the procedure, finds a new study in the American Journal of Preventive Medicine.

While colorectal cancer remains a leading cause of cancer-related death, the number of deaths has dropped over the past 20 years, according to the . The decrease is partly attributed to the fact that more people are receiving screening tests that catch sooner.

Researchers say that while decision-aid tools, such as descriptive videos and pamphlets, can help convince even more people to be tested, they aren't widely used yet.

"Although decision support tools such as ours have gained popularity, actual implementation into clinical practice has lagged because of perceived barriers related to the disruption of workflow in the clinic, time and potential costs," said lead author Paul C. Schroy, M.D., professor of medicine at Boston University School of Medicine.

The study included 825 primary care patients 50 to 75 years old with no symptoms and an average risk of , who were randomly divided into one of two intervention groups and one control group. During a routine visit with their , patients in the two intervention groups viewed a decision-aid video on the benefits and methods of or the video plus a personalized with feedback. Those in the control group were shown a generic healthy lifestyle video.

Patients were then queried 6 and 12 months after their office visit. The number of patients who completed a colorectal cancer screening test was about 8 percent higher for those in the decision aid group compared with the control group (43.1 vs. 34.8 percent, respectively)—which the researchers considered to be a "moderate impact" on .

"Decision aids are particularly useful when there is not a clear right or wrong treatment choice," explained Jennifer McClure, Ph.D., associate director of research at Group Health Research Institute in Seattle. "They can help patients make decisions that are well aligned with their personal values and health goals in the face of competing options, each of which has pros and cons." Decision aids are designed to complement rather than replace counseling from physicians.

Lead researcher Schroy said the challenge still remains to convince providers to implement decision aids into their practices outside of the context of a clinical trial.

"Until such time that the barriers can be addressed, we assume that physicians are more likely to utilize the more traditional, albeit less effective, verbal discussion," he said. 

Explore further: ACP releases new colorectal cancer screening guidance statement

More information: Schroy PC, Emmons KM, Peters E, et al. Aid-assisted decision-making and colorectal cancer screening: a randomized controlled trial. American Journal of Preventive Care. In Press, 2012.

Related Stories

ACP releases new colorectal cancer screening guidance statement

March 5, 2012
The American College of Physicians (ACP) today issued a new guidance statement for colorectal cancer screening. Colorectal cancer is the second leading cause of cancer-related deaths for men and women in the United States. ...

Study shows colorectal cancer screening rates high in patients with multiple health problems

March 20, 2012
A study by University of Kentucky researchers showed that in Appalachia, colorectal cancer screening rates were higher in the population with multiple morbidities or diseases compared to those who had no morbidities at all.

Many physicians recommend unnecessary cancer screening for the old and sick

June 4, 2012
A significant number of physicians would recommend colorectal cancer screening for elderly patients with a severe illness, according to David Haggstrom from the Richard L. Roudebush VA Medical Center in Indianapolis in the ...

Recommended for you

Study: Cells of three advanced cancers die with drug-like compounds that reverse chemo failure

January 23, 2018
Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggressive cancers—ovarian, prostate and breast.

'Hijacker' drives cancer in some patients with high-risk neuroblastoma

January 23, 2018
Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome "hijacks" DNA that regulates other genes. The resulting insights ...

Enzyme inhibitor combined with chemotherapy delays glioblastoma growth

January 23, 2018
In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

Scientists block the siren call of two aggressive cancers

January 23, 2018
Aggressive cancers like glioblastoma and metastatic breast cancer have in common a siren call that beckons the bone marrow to send along whatever the tumors need to survive and thrive.

Researchers identify a protein that keeps metastatic breast cancer cells dormant

January 23, 2018
A study headed by ICREA researcher Roger Gomis at the Institute for Research in Biomedicine (IRB Barcelona) has identified the genes involved in the latent asymptomatic state of breast cancer metastases. The work sheds light ...

Boosting cancer therapy with cross-dressed immune cells

January 22, 2018
Researchers at EPFL have created artificial molecules that can help the immune system to recognize and attack cancer tumors. The study is published in Nature Methods.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.